Rodent models of complement activation-related pseudoallergy: Inducers, symptoms, inhibitors and reaction mechanisms

European Journal of Nanomedicine

Volumn 7, Issue 1, 2015, Pages 15-25

  Dézsi, László ^a   Rosivall, László ^a,b   Hamar, Péter ^a   Szebeni, János ^a,c,d   Szénási, Gábor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SeroScience Ltd   (Hungary)

^d UNIVERSITY OF MISKOLC   (Hungary)

Author keywords

anaphylaxis; complement; liposomes; pseudoallergy; rats; rodents

Indexed keywords

BLOOD PRESSURE; CHEMICAL ACTIVATION; MAMMALS; NANOPARTICLES; RATING; RATS;

ANAPHYLAXIS; COMPLEMENT; COMPLEMENT ACTIVATIONS; HYPERSENSITIVITY REACTION; INTRAVENOUS ADMINISTRATION; ORDERS OF MAGNITUDE; PSEUDOALLERGY; RODENTS;

LIPOSOMES;

COBROTOXIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; HISTAMINE H2 RECEPTOR ANTAGONIST; LIPOSOME; NANOCARRIER; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE B2; ZYMOSAN;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE; COMPLEMENT ACTIVATION RELATED PSEUDOALLERGY; DRUG EFFECT; DYSPNEA; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL HAMSTER; EXPERIMENTAL RABBIT; EXTRAVASATION; HEART DISEASE; HEMATOCRIT; HEMOCONCENTRATION; LEUKOCYTOSIS; LEUKOPENIA; MOUSE; NONHUMAN; PREGNANCY; RAT; RESPIRATORY DISTRESS; REVIEW; THROMBOCYTOPENIA;

EID: 84924874585     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2015-0002     Document Type: Review

References (56)

1. Nath P, Basher A, Harada M, Sarkar S, Selim S, Maude RJ, et al. Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion. Trop Doct 2014;44:241-2.
2. Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, et al. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. PLoS Negl Trop Dis 2014;8:e2603.
3. Mukhtar M, Aboud M, Kheir M, Bakhiet S, Abdullah N, Ali A, et al. First report on Ambisome-associated allergic reaction in two Sudanese leishmaniasis patients. Am J Trop Med Hyg 2011;85:644-5.
4. Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 2012;30:4091-7.
5. Szebeni J, Bedocs P, Csukas D, Rosivall L, Bunger R, Urbanics R. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv Drug Deliv Rev 2012;64:1706-16.
6. Neun BW, Dobrovolskaia MA. Qualitative analysis of total complement activation by nanoparticles. Methods Mol Biol 2011;697:237-45.
7. Gal P, Dobo J, Beinrohr L, Pal G, Zavodszky P. Inhibition of the serine proteases of the complement system. Adv Exp Med Biol 2013;735:23-40.
8. Short AJ, Paczkowski NJ, Vogen SM, Sanderson SD, Taylor SM. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat. Br J Pharmacol 1999;128:511-4.
9. Dobrovolskaia MA, McNeil SE. In vitro assays for monitoring nanoparticle interaction with components of the immune system. In: Dobrovolskaia MA, McNeil SE, editors. Handbook of immunological properties of engineered nanomaterials. Singapore: World Scientific Publishing Company, 2013;581-638.
10. Szebeni J, Alving CR, Rosivall L, Bunger R, Baranyi L, Bedocs P, et al. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res 2007;17:107-17.
11. Dezsi L, Fulop T, Meszaros T, Szenasi G, Urbanics R, Vazsonyi C, et al. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. J Control Release 2014;195:2-10.
12. Gamaro GD, Suyenaga E, Borsoi M, Lermen J, Pereira P, Ardenghi P. Effect of rosmarinic and caffeic acids on inflammatory and nociception process in rats. ISRN Pharmacol 2011;2011:451682.
13. Proctor LM, Strachan AJ, Woodruff TM, Mahadevan IB, Williams HM, Shiels IA, et al. Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. Int Immunopharmacol 2006;6:1224-32.
14. Smedegard G, Cui LX, Hugli TE. Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol 1989;135:489-97.
15. Sato M, Sano H, Iwaki D, Kudo K, Konishi M, Takahashi H, et al. Direct binding of Toll-like receptor 2 to zymosan, and zymosaninduced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. J Immunol 2003;171:417-25.
16. Damas J. Involvement of platelet-activating factor in the hypotensive response to zymosan in rats. J Lipid Mediat 1991;3:333-44.
17. Damas J, Bourdon V, Remacle-Volon G, Adam A. Kinins and peritoneal exudates induced by carrageenin and zymosan in rats. Br J Pharmacol 1990;101:418-22.
18. Damas J, Lagneaux D. Dissociation between the effects of zymosan on the systemic and pulmonary vessels of the rat. Br J Pharmacol 1991;104:559-64.
19. Damas J, Remacle-Volon G. Mast cell amines and the oedema induced by zymosan and carrageenans in rats. Eur J Pharmacol 1986;121:367-76.
20. Damas J, Remacle-Volon G, Bourdon V. Platelet-activating factor and the vascular effects of zymosan in rats. Eur J Pharmacol 1993;231:231-6.
21. Damas J, Remacle-Volon G, Nguyen TP. Inhibition by WEB 2086, a PAG-acether antagonist of oedema and peritonitis induced by zymosan in rats. Arch Int Pharmacodyn Ther 1990;306:161-9.
22. Szebeni J, Bedocs P, Rozsnyay Z, Weiszhar Z, Urbanics R, Rosivall L, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 2012;8:176-84.
23. Hoffman MC, Rumer KK, Kramer A, Lynch AM, Winn VD. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol 2014;71:55-60.
24. Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/ HELLP syndrome. Placenta 2013;34:201-3.
25. Lillegard KE, Loeks-Johnson AC, Opacich JW, Peterson JM, Bauer AJ, Elmquist BJ, et al. Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats. J Pharmacol Exp Ther 2014;351:344-51.
26. Rabinovici R, Rudolph AS, Feuerstein G. Characterization of hemodynamic, hematologic, and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. Circ Shock 1989;29:115-32.
27. Rabinovici R, Rudolph AS, Feuerstein G. Improved biological properties of synthetic distearoyl phosphatidyl choline-based liposome in the conscious rat. Circ Shock 1990;30:207-19.
28. Rabinovici R, Rudolph AS, Vernick J, Feuerstein G. Lyophilized liposome encapsulated hemoglobin: evaluation of hemodynamic, biochemical, and hematologic responses. Crit Care Med 1994;22:480-5.
29. Rabinovici R, Rudolph AS, Yue TL, Feuerstein G. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. Circ Shock 1990;31:431-45.
30. Szebeni J, Wassef NM, Spielberg H, Rudolph AS, Alving CR. Complement activation in rats by liposomes and liposomeencapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Commun 1994;205:255-63.
31. Szebeni J, Spielberg H, Cliff RO, Wassef NM, Rudolph AS, Alving CR. Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1. Artif Cells Blood Substit Immobil Biotechnol 1997;25:347-55.
32. Moghimi SM, Hamad I, Andresen TL, Jorgensen K, Szebeni J. Methylation of the phosphate oxygen moiety of phospholipidmethoxy( polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006;20:2591-3.
33. Muschick P, Sachse A, Leike J, Wehrmann D, Krause W. Lipid Dependent Cardio-Haemodynamic Tolerability of Liposomes in Rats. J Liposome Res 1995;5:933-53.
34. Krause W, Gerlach S, Muschick P. Prevention of the hemodynamic effects of iopromide-carrying liposomes in rats and pigs. Invest Radiol 2000;35:493-503.
35. Muschick P, Wehrmann D, Schuhmann-Giampieri G, Krause W. Cardiac and hemodynamic tolerability of iodinated contrast media in the anesthetized rat. Invest Radiol 1995;30:745-53.
36. Marceau F, Lundberg C, Hugli TE. Effects of the anaphylatoxins on circulation. Immunopharmacology 1987;14:67-84.
37. Fraser DG, Regal JF. C5a/C5ades-Arg-induced increase in blood pressure in the guinea pig: role of thromboxane. Immunopharmacology 1990;19:59-68.
38. Fraser DG, Regal JF. Recombinant human C5a-induced bronchoconstriction in the guinea pig: inhibition by an H1 antagonist after depletion of circulating granulocytes and platelets. J Pharmacol Exp Ther 1991;259:1213-20.
39. Regal JF, Fraser DG. Recombinant human C5a-induced bronchoconstriction in the guinea-pig: a histamine independent mechanism. Pulm Pharmacol 1990;3:79-87.
40. Regal JF, Klos A. Minor role of the C3a receptor in systemic anaphylaxis in the guinea pig. Immunopharmacology 2000;46:15-28.
41. Proctor LM, Moore TA, Monk PN, Sanderson SD, Taylor SM, Woodruff TM. Complement factors C3a and C5a have distinct hemodynamic effects in the rat. Int Immunopharmacol 2009;9:800-6.
42. Morganroth ML, Schoeneich SO, Till GO, Ward PA, Horvath SJ, Glovsky MM. C3a57-77, a C-terminal peptide, causes thromboxane-dependent pulmonary vascular constriction in isolated perfused rat lungs. Am Rev Respir Dis 1990;141:296-300.
43. Lundberg C, Marceau F, Hugli TE. C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol 1987;128:471-83.
44. Kajita T, Hugli TE. C5a-induced neutrophilia. A primary humoral mechanism for recruitment of neutrophils. Am J Pathol 1990;137:467-77.
45. Bjork J, Hugli TE, Smedegard G. Microvascular effects of anaphylatoxins C3a and C5a. J Immunol 1985;134:1115-9.
46. Banda NK, Mehta G, Chao Y, Wang G, Inturi S, Fossati-Jimack L, et al. Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. Part Fibre Toxicol 2014;11:64.
47. Wang H, Cheng G, Du Y, Ye L, Chen W, Zhang L, et al. Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation. Mol Med Rep 2013;7:947-52.
48. Kolaczkowska E, Seljelid R, Plytycz B. Role of mast cells in zymosan-induced peritoneal inflammation in Balb/c and mast cell-deficient WBB6F1 mice. J Leukoc Biol 2001;69:33-42.
49. Kanaoka Y, Maekawa A, Penrose JF, Austen KF, Lam BK. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J Biol Chem 2001;276:22608-13.
50. Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother 2007;51:1078-81.
51. Regal JF, Fraser DG, Anderson DE, Solem LE. Enhancement of antigen-induced bronchoconstriction after intravascular complement activation with cobra venom factor. Reversal by granulocyte depletion. J Immunol 1993;150:3496-505.
52. Heller A, Kunz M, Samakas A, Haase M, Kirschfink M, Koch T. The complement regulators C1 inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits. Shock 2000;13:285-90.
53. Hsueh W, Sun X, Rioja LN, Gonzalez-Crussi F. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 1990;70:309-14.
54. Bult H, Herman AG, Laekeman GM, Rampart M. Formation of prostanoids during intravascular complement activation in the rabbit. Br J Pharmacol 1985;84:329-36.
55. Tousignant JD, Gates AL, Ingram LA, Johnson CL, Nietupski JB, Cheng SH, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 2000;11:2493-513.
56. Kiang A, Hartman ZC, Everett RS, Serra D, Jiang H, Frank MM, et al. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther 2006;14:588-98.